HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients.
It has been demonstrated that patients on highly active antiretroviral therapy are at increased risk for developing metabolic abnormalities that include elevated levels of serum triglycerides and low-density lipoprotein cholesterol and reduced levels of high-density lipoprotein cholesterol. This dyslipidemia is similar to that seen in the metabolic syndrome, raising the concern that highly active antiretroviral therapy also potentially increases the risk for cardiovascular complications. This paper reviews the contribution of both HIV infection and the different components of highly active antiretroviral therapy to dyslipidemia and the role of these abnormalities toward increasing the risk of cardiovascular disease in HIV-infected patients; therapeutic strategies to manage these risks are also considered.
Kotler
Donald P
DP
Division of Gastroenterology, Department of Medicine, St. Luke's-Roosevelt Hospital Center, College of Physicians & Surgeons, Columbia University, New York, NY 10025, USA. dpkotler@aol.com
D019380:Anti-HIV Agents / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000150:complications; D050171:Dyslipidemias / Q000178:diet therapy / Q000209:etiology*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D039682:HIV-Associated Lipodystrophy Syndrome / Q000178:diet therapy / Q000209:etiology*; D006801:Humans; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood; D012306:Risk
D019380:Anti-HIV Agents; D008055:Lipids